IPP Bureau
Takeda and Innovent Biologics forge global partnership to advance oncology medicines for solid tumors
By IPP Bureau - October 23, 2025
Takeda will make an upfront payment of $1.2 billion, which includes a $100 million equity investment in Innovent
Biocon Biologics secures Health Canada nod for biosimilars Yesintek, Yesintek IV
By IPP Bureau - October 23, 2025
Yesintek and Yesintek I.V. are approved for the treatment of moderate to severe plaque psoriasis in adults and pediatric patients
FDA grants priority review to Merck’s KEYTRUDA and KEYTRUDA QLEX combos with Padcev for muscle-invasive bladder cancer
By IPP Bureau - October 23, 2025
The submissions are supported by data from the Phase 3 KEYNOTE-905 trial
Pimicotinib delivers lasting tumor responses and sustained symptom relief in TGCT patients
By IPP Bureau - October 23, 2025
Global Phase 3 MANEUVER study highlights ongoing benefits and consistent safety profile
ACG to invest $200 million in US hard-shell capsule manufacturing
By IPP Bureau - October 22, 2025
The initial $100 million will fund a state-of-the-art hard-shell capsule facility in Atlanta
FDA approves Roche’s kidney inflammation drug
By IPP Bureau - October 22, 2025
Gazyva/Gazyvaro is the only anti-CD20 monoclonal antibody to demonstrate a complete renal response benefit in lupus nephritis in a randomised phase III study
AstraZeneca’s Imfinzi cuts death risk by 32% in high-risk non-muscle-invasive bladder cancer
By IPP Bureau - October 22, 2025
Adding one year of Imfinzi treatment to Bacillus Calmette-Guérin (BCG) induction and maintenance therapy delivered an early and sustained disease-free survival benefit vs. BCG alone
AbbVie completes acquisition of Gilgamesh Pharmaceuticals' Bretisilocin
By IPP Bureau - October 22, 2025
Acquisition expands AbbVie's psychiatry pipeline with the addition of a next-generation psychedelic compound currently in Phase 2 development for the treatment of major depressive disorder
Enzalutamide leads to 40% lower risk of death in prostate cancer
By IPP Bureau - October 22, 2025
XTANDI is the first and only androgen receptor inhibitor-based regimen to demonstrate overall survival benefit in this patient population, supporting its earlier use in this setting
Pfizer’s Braftovi+Mektovi shows sustained long-term survival in patients with advanced lung cancer
By IPP Bureau - October 22, 2025
Results from the Phase 2 PHAROS trial potentially establish new benchmark with targeted combination therapies for this patient population
Merck breaks ground on $3 billion center of excellence for pharma manufacturing in Virginia
By IPP Bureau - October 22, 2025
The expansion underscores Merck’s commitment to invest more than $70 billion in U.S. research, development and capital projects
Bajaj Healthcare posts Q2 FY26 PAT at Rs. 11.10 Cr
By IPP Bureau - October 22, 2025
Bajaj Healthcare has reported total income of Rs. 149.56 crore during the period ended September 30, 2025
TTK Healthcare reports Q2 FY26 net profit at Rs. 20.38 Cr
By IPP Bureau - October 22, 2025
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
Qure.ai receives regulatory clearance for AI tool for early detection of TB in children below 3 years
By IPP Bureau - October 22, 2025
Breakthrough expands proactive TB screening from birth to 15 years, ensuring faster and more accurate diagnosis
RPG Life Sciences posts Q2 FY26 PAT at Rs. 36.85 Cr
By IPP Bureau - October 22, 2025
RPG Life Sciences has reported total income of Rs. 186.22 crore during the period ended September 30, 2025
